Clinical Cardiology

View the latest content related to this topic

News Daily News

Coronary CTA Reimbursement for US Hospitals Will Double in 2025

The change reflects a growing understanding of what resources are needed to offer these scans and will likely improve access.

Yael L. Maxwell

November 08, 2024

Slides

See all

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond R. Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael A. Weber

October 29, 2024

News

See all

News Daily News

Coronary CTA Reimbursement for US Hospitals Will Double in 2025

By Yael L. Maxwell

November 08, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

By Michael O'Riordan

November 07, 2024

News Conference News VIVA 2024

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

By L.A. McKeown

November 07, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

By L.A. McKeown

November 06, 2024

News Daily News

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

By Caitlin E. Cox

November 06, 2024

New York Valves 2024

June 5

June 07, 2024

EuroPCR 2024

May 14

May 17, 2024

ACC 2024

April 6

April 08, 2024

Videos on This Topic

See all

Advertisement

Clinical Cardiology

Coronary CTA Reimbursement for US Hospitals Will Double in 2025

Slides

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

News

Coronary CTA Reimbursement for US Hospitals Will Double in 2025

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

More on This Topic

Conference Coverage

New York Valves 2024

EuroPCR 2024

ACC 2024

Videos on This Topic

Advertisement

Clinical Cardiology

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content